OncLive TV

Marc J. Braunstein, MD, PhD, discusses the expanding treatment armamentarium in multiple myeloma.

Reema A. Patel, MD, discusses findings from the NAPOLI-1 trial in pancreatic cancer.

Pashtoon M. Kasi, MD, MS, ​discusses findings from the CRC-MRD Consortia in colorectal cancer.

Nathan Bahary, MD, PhD, discusses the role of pemigatinib in biliary tract cancers.

Robert M. Rifkin, MD, FACP, discusses corneal toxicities with belantamab mafodotin-blmf in multiple myeloma.

Ghulam Rehman Mohyuddin, MD, discusses improving survival for patients with multiple myeloma.

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in myelofibrosis.

Michael E. Hurwitz, MD, PhD, compares the utility of antiandrogens in nonmetastatic castration-resistant prostate cancer.

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.

Mehmet K. Samur, PhD, discusses the evolving treatment landscape in multiple myeloma.

Timothy Price, MBBS, DHthSc, FRACP, discusses the rationale to evaluate sotorasib in gastrointestinal cancers.

Mario Sznol, MD, discusses the challenges of managing immune-related toxicities in melanoma.

Nina Shah, MD, discusses the importance of assessing quality of life in multiple myeloma.

Gaby Hobbs, MD, discusses managing ponatinib-associated toxicities in chronic myeloid leukemia.

Michael B. Atkins, MD, discusses the benefits of neoadjuvant therapy in melanoma.

Kendra Sweet, MD, discusses treatment selection with TKIs in chronic myeloid leukemia.

Ryan Sullivan, MD, discusses treatment options in BRAF-mutant melanoma.

Michael J. Cavnar, MD, discusses ​surgical differences between right- and left-sided tumors in colorectal cancer.

Prakash Pandalai, MD, discusses the development of peritoneal carcinomatosis in colorectal cancer.

Prakash Pandalai, MD, ​discusses the use of cytoreductive surgery plus heated intraperitoneal chemotherapy in the treatment of patients with colorectal peritoneal carcinomatosis.

Eunice Wang, MD, discusses preliminary findings from the ongoing KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Thomas Powles, MBBS, MRCP, MD, discusses the role of circulating tumor DNA positivity in high-risk muscle-invasive urothelial cancer.

Lajos Pusztai, MD, DPhil, discusses the role of circulating tumor DNA as a biomarker of response in patients with high-risk early-stage breast cancer.

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of pevonedistat in myelodysplastic syndrome.

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Yelena Y. Janjigian, MD, discusses the emergence of new treatment options in esophageal and gastric cancer.

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Jeffrey S. Weber, MD, PhD, discusses unmet needs in melanoma.